home / stock / srzn / srzn message board
Subject | By | Source | When |
---|---|---|---|
What's up with all the 100 share buys? | csud1 | investorshub | 02/10/2023 7:19:31 PM |
znewcar1: $SRZN 46% v9,2M c1.13 f29,740M H1.18 ML.5313 gapNgo to hod | znewcar1 | investorshangout | 02/09/2023 9:09:44 PM |
Great day | Joelzee | investorshub | 02/09/2023 8:01:19 PM |
Buying .60s | BEIJING BILL | investorshub | 12/28/2022 6:43:12 PM |
sexy dilution lol>https://twitter.com/ThePberg/status/1602077645516472320/photo/1 | 81vette | investorshub | 12/15/2022 5:06:46 PM |
where?,post link,dilution lol,gapping/running 50% is dilution how? | 81vette | investorshub | 12/15/2022 5:04:50 PM |
no shares to short=100s% win possible>0 2022-12-15 11:30:03,8.39% | 81vette | investorshub | 12/15/2022 4:40:49 PM |
book value per share (mrq) $2.21 | 81vette | investorshub | 12/15/2022 3:55:24 PM |
Dilution news | willlbone | investorshub | 12/15/2022 3:49:13 PM |
no shares to short!!>Zero Borrow,Shares Outstanding 34.97M,Shares Float,32.70 | 81vette | investorshub | 12/15/2022 3:47:37 PM |
loaded .46 ,bounce babe,bounce!!! ;-) | 81vette | investorshub | 12/15/2022 3:32:31 PM |
Big volume today. | willlbone | investorshub | 12/15/2022 1:24:57 AM |
So, I guess I'll try making a post | l3gionFX | investorshub | 11/17/2022 6:30:53 PM |
znewcar1: SRZN 36% v9,6M c9.90 f36,4M H12.27 | znewcar1 | investorshangout | 09/07/2021 8:07:40 PM |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 109.0% to $0.3668 on volume of 102,385,159 shares Maxeon Solar Technologies Ltd. (MAXN) rose 4.3% to $0.181 on volume of 66,422,365 shares NVIDIA Corporation (NVDA) fell 1.3% to $126.58 on volume...
Targeted protein degradation (TPD * ) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific a...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1...